Ochre Ideas

Rethinking liver therapy discovery and development

“The scale of Ochre's work is uniquely powered to address the complexities of liver disease.”

"Ochre embodies an unprecedented convergence of computational and multi-omic technologies. Truly a next-generation platform for solving liver disease."

"The future of chronic liver disease treatment is being shaped by Ochre Bio, built by some of the best scientific talent on a foundation of transdisciplinary excellence."

“The scale of Ochre's work is uniquely powered to address the complexities of liver disease.”

"Ochre embodies an unprecedented convergence of computational and multi-omic technologies. Truly a next-generation platform for solving liver disease."

"The future of chronic liver disease treatment is being shaped by Ochre Bio, built by some of the best scientific talent on a foundation of transdisciplinary excellence."

WHAT

Using human models to generate genomic and phenotypic data at scale, we're developing RNA therapies for the biggest liver health challenges.

WHY

Chronic liver disease is the only top ten global killer on the rise.

"Liver disease is the third leading cause of premature death." UK Health Security Agency, July 2021

Chronic liver disease affects millions of patients worldwide, with the prevalence rising. Despite the recent first approval of a therapy for MASH, a high unmet need remains for patients with late stage disease, where for many patients the only treatment remains a liver transplant.

European Health for All database. Data missing in 2000.

HOW

Human Discovery

We deep phenotype human liver samples and models at scale to causally map genes to cells to histology and clinical data.

Human Validation

Ochre’s validation platform is among the world’s most advanced in human systems, from human cell co-culture, to diseased liver tissue culture, to the perfusion of whole human livers.

RNA Therapies

Our RNA chemistry platform not only develops therapies with a greater chance of clinical success, it allows Ochre’s scientists to progress a target to a validated lead using human data in weeks, not years.